Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCI Biotech Holding ASA

This article was originally published in Start Up

Executive Summary

PCI Biotech Holding is developing a light-directed drug delivery system with the potential to make drug delivery more efficient and targeted, and to reduce overall toxicity. The company's technology is based on the fact that cells absorb molecules, including proteins and other biological macromolecules, drug carriers such as antibodies and nanoparticles, and some small molecules, by engulfing them with the cell membrane, in a process called endocytosis. This creates an endosome, a small "bubble" of cell membrane enclosing the absorbed molecules. For the biologically active molecules to interact with the intracellular targets, they must be released from the endosome into the cytosol in a process called "endosomal escape."

You may also be interested in...



Start-Up Previews (04/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Stem Cell Therapies," features profiles of Amorcyte, California Stem Cell, Cardio3 BioSciences, CellDesign and Fate Therapeutics. Plus these Start-Ups Across Health Care: Alaxo, CorNova, PCI Biotech.

Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer

Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel